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Abstract: 
Background: Chronic kidney disease (CKD) affects approximately 13% of the adult population, resulting in 
significant morbidity, mortality and health care costs.  
Method: A Cross-sectional study was conducted among Patients with type II diabetes or hypertension or both in 
chronic disease clinics (CDC) in PHC centers in Eastern Province to assess adherence to nephropathy screening 
guideline among physicians in chronic disease clinics.  
Results:  The study included 246 patients, the majority 51.6% was females. 40.2% of patients had type 2 diabetes 
mellitus, 24.4% had hypertension and 35.4% had both. There were only 26% of cases follow guideline in screening 
of nephropathy.  
Conclusion: The study concluded that the majority of cases do not follow nephropathy screening guideline. We 
recommend decision makers to conduct further planning on increasing the adherence level and the outcomes of the 
screening program. 
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BACKGROUND: 
Chronic kidney disease (CKD) is a major health 
problem in Saudi Arabia. There has been a noticeable 
rise in the prevalence and incidence of end stage 
chronic kidney disease (CKD) in Saudi Arabia over 
the last three decades. This rise exceeds those reported 
from many countries. Diabetic nephropathy and 
hypertensive nephropathy are the two major causes of 
CKD (43%, and 36% respectively). Deaths from 
ESRD were 2.21% annually. Of those 12% dying with 
CKD in Saudi Arabia annually, we estimated that two 
thirds were diabetics.1 
 
The prevalence of diabetic nephropathy among 
dialysis patients in Saudi Arabia has increased by 
162% in the last twenty-five years.1 Hypertension, on 
the other hand, affects more than 25% of the adult 
Saudi population.2 Perform an annual test to assess 
urine albumin excretion in all type 2 diabetic patients 
starting at diagnosis. Measure serum creatinine at least 
annually in all adults with diabetes regardless of the 
degree of urine albumin excretion. 3 
 
According to NICE guidelines, CKD is classified into 
5 grades based on glomular filtration rate (GFR) and 
Albumin Creatinine Ratio (ACR) : (Normal : 90<=, 
Mild : 89-60, Moderate: 59-30, Severe : 29-15 and 
:Kidney Failure: 15>=).4 
 
Kidney disease often has no symptoms in its early 
stage, therefore, adherence to nephropathy screening 
program plays a vital role in early detection, 
intervention, and treatment. 
Frequency of requesting renal profile based on Saudi 
National Nephropathy screening guidelines (as 
recommendation from American Diabetics 
Association ADA2017)5,6, is to be run annually for all 
patients, every 6 months if eGFR 45-60 
ml/min/1.73m2, every 3 months if eGFR 30-44 
ml/min/1.73m2. 
 
LITERATURE REVIEW: 
Microalbuminuria is considered the earliest sign of 
Diabetic nephropathy. In Saudi National diabetic 
registry study which was done in 54,670 type 2 
diabetic patients, 10.8% of them have diabetic 
nephropathy divided into 1.2% Microalbuminuria, 8.1 
Macroalbuminurea and 1.5% End Stage Renal 
Disease. 7 
By the end of 2008, there were 10,203 patients on 
hemodialysis, 966 on peritoneal dialysis, and 
7836 with functioning kidney grafts.  Of the current 
patients on hemodialysis, 42.5% were diabetic. The 
prevalence of renal replacement therapy (RRT) has 
increased from 361 per million population (PMP) in 
1995 to 874 PMP in 2008. Over the same period, the 
dialysis patient prevalence has increased from 187 to 
463 PMP.  The prevalence of ESRD in the USA 
increased from 1150 PMP in 1995 to 1698 PMP in 
2007 and in dialysis from 710 to 1076 PMP.2 
 
A cross sectional study was done in Netherlands and 
carried out on 15,954 patients with type 2 diabetes or 
hypertension showed that the prevalence of CKD was 
28% in patients with diabetes and 21% in patients with 
hypertension.8 
 
Screening for CKD in primary care is low as Data from 
2001 to 2004 showed that in Netherlands only 33% of 
patients with hypertension or diabetes are screened 
yearly for serum creatinine, and 10% of patients with 
diabetes are screened for albuminuria.8 
Cross-sectional study carried out in India showed that 
most physicians reported performing routine 
urinalysis annually on the majority of their patients as 
recommended by the ADA. Most 86% of physicians 
reported conducting urinalysis on more than half of 
their type 1 patients as did 82% for their type 2 
patients.  Approximately 85% of physicians who 
screen their patients for albuminuria reported using 
urine dipsticks most often.9 
 
OBJECTIVE: 
To assess adherence to nephropathy screening 
guideline among physicians in chronic disease clinics. 
 
SUBJECTS & METHODS: 
Study design, setting and period: The study is a 
cross-sectional study carried out on Patients with type 
II diabetes or hypertension or both in chronic disease 
clinics (CDC) in 4 different PHC centers in Eastern 
Province from the period of January to July, 2019. The 
PHC centers are Aljiser District PHC, Alaqrabiyah 
PHC, Ibn Hayan PHC, Alkhozama PHC. 
 
Sample size: We assumed prevalence 50%, a 
precision 5%, an alpha level of 5%, the calculated 
minimum sample size is 246 patient's file. 
 
Inclusion Criteria: Patients’ files in chronic disease 
clinic for male and female, diagnosed with type II 
diabetes, hypertension or both with or without other 
comorbidities. 
 
Exclusion Criteria: Type I diabetes mellitus and other 
chronic diseases. 
 
IAJPS 2019, 06 [08], 15077-15084              Esam Yahya Qugandi et al            ISSN 2349-7750 
 
w w w . i a j p s . c o m  
 
Page 15079 
Sampling technique: Accredited trainees of the 
family medicine training program from the PHC 
centers were collecting the data through unified data 
extraction sheets.  
 
Data collection tools: Data extraction sheet designed 
for the purpose of this study will be used. The form 
contained variables such as Age, Sex, Smoking status, 
Blood pressure (BP), HbA1C, creatinine level, eGFR, 
proteinuria, Urine albumin creatinine ratio (UACR) 
and referral.  
 
Study procedures: Then, we collected the total 
number of type II DM, hypertensive patients or both 
in chronic disease clinics who follow up regularly 
from all centers. After that, we selected the 
consecutive sample from the total. 
Data was collected by using data extraction sheet 
through reviewing medical records which were filled 
by investigators. Recommended tests data were 
collected for the past one year (from January to 
December 2018). The study was carried out during 
December 2018. 
 
Data management and statistical analysis: The 
collected data were entered and analyzed using the 
Statistical Package for the Social Science (SPSS Inc. 
Chicago, IL, USA) version 23. Descriptive statistics 
was performed. Percentages were given for qualitative 
variables and Mean (±SD) were given for quantitative 
variables. The primary study outcome (prevalence of 
adherence to DN screening according to Saudi 
Guidelines) were presented as percentage and 95% CI. 
 
Ethical consideration: Privacy of patients’ 
information and confidentiality were carefully 
maintained. We received approval from family 
medicine joint program director which was given to 
primary health care center managers to conduct our 
study.  
 
RESULTS: 
Table (1): The study included 246 patients, the 
majority 51.6% was females and 48.4%males. There 
were 73.2% Saudi and 26.8% non-Saudi. There 
majority of patients were never smoker 76.4% 
followed by 18.7% smokers and only 4.9%were ex-
smokers. 40.2% of patients had type 2 diabetes 
mellitus, 24.4% had hypertension and 35.4% had both. 
Blood pressure was controlled in 69.9 %of patients. 
HbA1c was >=7 in 41.9% of patients, <7 in 31.7% and 
not done in 25.2%of them. More than half of patients 
(56.9%) had serum creatinine (1) in past 1 years, 
67.5% had 0 ACR number and 93.5%of them had 0 
proteinuria in past 1 year.  
 
Table (2): Regarding to guideline following, there 
were 26% of cases follow guideline in screening. 
 
Table (3): 16.3% of patients had moderate (60-89) 
eGFR, 11.4% had high (>=90) eGFR and 10.6% had 
low (<60) eGFR. In males 25.6% had normal 
creatinine levels followed by high in 6'9% of them 
however, in females the majority (21.5%) had high 
level in creatinine followed by normal in 13% of them. 
 
Table (4): As regards relation between guideline 
following and sociographic characters, there were no 
significant correlations with age and gender. Also, 
there was no relation found with diagnosis of patients 
and nationality (P>0.05).
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Table (1): Patients’ clinical data (N=246) 
VARIABLE NO. % 
Primary Health Care Center (PHC)   
 Aljiser District PHC 62 25.2 
 Alaqrabiyah PHC 66 26.8 
 Ibn Hayan PHC 57 23.2 
 Alkhozama PHC 61 24.8 
Gender   
 Male 119 48.4 
 Female 127 51.6 
Age Groups (years)   
 ≥70 29 11.8 
 51-69 135 54.9 
 ≤50 82 33.3 
Nationality   
 Saudi 180 73.2 
 Non-Saudi 66 26.8 
Smoking 
 Current smoker 46 18.7 
 Never smoker 188 76.4 
 Ex-smoker 12 4.9 
Diagnosis 
 Type II DM 99 40.2 
 Hypertension 60 24.4 
 Both 87 35.4 
BP Control (Based on the last 3 readings) 
 Controlled 172 69.9 
 Uncontrolled 33 13.4 
 N/A 41 16.7 
HbA1C (Latest value in the past 1 year) 
 <7 78 31.7 
 ≥7 103 41.9 
 Not done 62 25.2 
 N/A 3 1.2 
Number of serum creatinine in past 1 year 
 None 69 28.0 
 1 140 56.9 
 2 30 12.2 
 3 7 2.8 
Number of ACR in past 1 year 
 None 166 67.5 
 1 61 24.8 
 2 15 6.1 
 3 4 1.6 
Number of proteinuria in past 1 year 
 None 230 93.5 
 1 13 5.3 
 2 3 1.2 
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Table (2): Guideline following; frequency and 95% CI. 
GUIDELINES FOLLOWED NO. % 95% CONFIDENCE INTERVAL (CI) 
Followed 64 26.0 
(20%-32%) Not Followed 182 74.0 
 
Table (3): Distribution of the results of eGFR and Serum Creatinine levels in males and females. 
VARIABLES NO. % 
eGFR   
 High (>=90) 28 11.4 
 Moderate (60-89) 40 16.3 
 Low (<60) 26 10.6 
 Total 94 38.2 
 N/A 152 61.8 
Mean (+SD) 77.5(27.0) 
Creatinine Levels Males (N=89)   
 High 17 6.9 
 Normal 63 25.6 
 Low 9 3.7 
 Missing 28 5.3 
Mean (+SD) 89.64(22.16) 
Creatinine levels (Females) (N=127)   
 High 53 21.5 
 Normal 32 13.0 
 Low 2 .8 
 N/A 40 64.6 
Mean (+SD) 94.9(29.9) 
 
 
 GUIDELINES FOLLOWING  
TOTAL 
(N=246) 
 
P VALUE  Followed (n=64) Not Followed 
(n=182) 
Age Group (years) 
 ≥ 70 10 (34.5%) 19 (65.5%) 29 (100.0%) 0.538 
 51-69 34 (25.2%) 101 (74.8%) 135 (100.0%)  
 ≤50 20 (24.4%) 62 (75.6%) 82 (100.0%)  
Gender 
 Male 31 (26.1%) 88 (73.9%) 119 (100.0%) 0.553 
 Female 33 (26.0%) 94 (74.0%) 127 (100.0%)  
Diagnosis 
 Type II DM 29 (29.3%) 70 (70.7%) 99 (100.0%) 0.607 
 Hypertension 15 (25.0%) 45 (75.0%) 60 (100.0%)  
 Both 20 (23.0%) 67 (77.0%) 87 (100.0%)  
Nationality 
 Saudi 47 (26.1%) 133 (73.9%) 180 (100.0%) 0.548 
 Non-Saudi 17 (25.8%) 49 (74.2%) 66 (100.0%)  
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DISCUSSION: 
Chronic kidney disease (CKD) is a major global health 
problem with an increasing prevalence, due to aging 
of the population and rising incidence of hypertension 
and diabetes [10]. CKD is associated with a high risk 
of cardiovascular morbidity, mortality and 
deterioration to end-stage renal disease (ESRD) [11]. 
CKD represents a significant public health problem, 
with nearly 20 million people in the United States 
having kidney damage or reduced kidney function 
[12]. More than 400,000 people currently receive 
some form of renal replacement therapy, and this 
number is expected to reach 2.2 million by the year 
2030 [13]. Chronic kidney disease (CKD), defined as 
either decreased glomerular filtration rate (GFR) or 
albuminuria, or both [11]. Also, it is defined by 
indicators of kidney damage—imaging or proteinuria 
(commonly using albumin to creatinine ratio, ACR)—
and decreased renal function (below thresholds of 
GFR estimated from serum creatinine concentration) 
[14, 15].  
 
Diabetes and hypertension are major causes of CKD 
[16]. Therefore, current international guidelines 
recommend yearly screening for CKD in patients with 
diabetes or hypertension [17, 18]. Diabetes is the 
leading cause of CKD, demonstrated for 33% of the 
adult cases with CKD [19]. Nevertheless, 20% to 40% 
of diabetics will develop diabetic nephropathy during 
the end stage of their disease [20]. The initial 
presentation of diabetic kidney disease is 
microalbuminuria followed by increasing severity of   
proteinuria   as   the   glomerular   filtration   membrane   
is damaged [21].  Also, hypertension represents a 
powerful risk factor for CKD and is almost fixedly 
found in patients with renal failure. Sodium retention 
and activation of the renin-angiotensin system have 
been regarded as the most effective mechanisms 
implicated in the rising of blood pressure in patients 
with CKD [22]. 
 
Guidelines can be defined as a document that 
streamlines particular processes according to a regular 
routine. In the medical context it refers to a document 
which seeks to guide decisions and criteria regarding 
diagnosis, management/treatment in specific areas of 
healthcare [23]. Guidelines identify, summarize and 
evaluate evidence of the highest quality and the most 
up-to-date data about prevention, diagnosis, 
prognosis, therapy including dosages of medications, 
risk/benefit and cost-effectiveness [24]. There are a 
variety of barriers to guideline adherence, of which the 
doctor, patient and practice factors play an important 
role. According to adherence to guidelines in 
screening of nephropathy, our study reported that there 
were 26% of cases followed guidelines in screening.  
Generally, compliance with screening for CKD by 
primary care providers is low [25]. Another study 
found that overall, adherence by GPs to the guideline 
recommendations regarding a consultation or referral 
was low [26].  Also, another study reported only 8.3% 
of the patient's recommendations from CKD 
guidelines with respect to consultation and referral to 
specialist care were followed [27].  However, another 
study conducted among patients with type II diabetes 
reported; compliance rate for microalbuminuria 
screening was 56.3% which was higher than the 
quoted national average of 14–49% [28]. 
 
Currently, screening for chronic kidney disease is 
accepted practice only in patients with hypertension or 
diabetes, [29] but more widespread screening is 
increasingly proposed [30]. The United Kingdom 
chronic kidney disease guidelines also recommend at 
least annual screening of all adults at risk of 
obstructive kidney disease and those with prevalent 
cardiovascular diseases, [31] while the US kidney 
disease outcomes quality initiative (US KDOQI) 
guidelines use age >60 for additional inclusion [14]. 
Both guidelines highlight the risk associated with 
multisystem diseases and nephrotoxic drugs. Although 
evidence to recommend routine screening is 
insufficient, the tests often suggested for screening 
CKD that are feasible in primary care include 
creatinine-derived estimates of glomerular filtration 
rate (GFR), as well as urine testing for albumin (micro- 
or microalbuminuria) [32]. Current Kidney Disease: 
Improving Global Outcomes (KDIGO) guidelines 
encourage clinicians to monitor both GFR and 
albumin annually—more frequently in selected 
patients—to consider the risk of disease progression 
and therapeutic management [33]. 
 
Regarding to screening tests, our study found that 
16.3% of patients had moderate (60-89) eGFR, 11.4% 
had high (>=90) eGFR and 10.6% had low (<60) 
eGFR. In males 25.6% had normal creatinine levels 
followed by high in 6'9% of them however, in females 
the majority (21.5%) had high level in creatinine 
followed by normal in 13% of them. 
 
As regards relation between guideline following and 
sociographic characters, our study found that there 
were no significant correlations with age and gender. 
Also, there was no relation found with diagnosis of 
patients and nationality (P>0.05). 
 
CONCLUSION: 
The study concluded that the majority of cases do not 
follow nephropathy screening guideline. Therefore, 
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we recommend decision makers to conduct further 
planning on increase awareness to physicians and 
patient about importance of nephropathy screening 
program , and making physicians perform all the 
screening measures according to the provided 
guidelines in order to increase the adherence level and 
the outcomes of the screening program.  
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